SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Can Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis - Frank KloproggeView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Ethionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis - Charles PeloquinView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Exposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial - Chishala ChabalaView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Co-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial - Elisa IgnatiusView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB - Ahmed Aliyu AbulfathiView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Relationship Between Plasma and Intracellular Concentrations of Bedaquiline and its M2 Metabolite in South African Patients with Drug-Resistant TB - Precious NgwaleroView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Evaluating Hepatotoxicity of Bedaquiline Treatment in Multi-Drug Resistant Tuberculosis Patients - Lénaïg TanneauView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Oxazolidinones for TB: Current Status and Future Prospects - Lawrence GeiterView Slideset
MRManuel Romero-GomezMDSlidesetViral Hepatitis and Liver DiseaseEuropean Workshop on NASH in Clinical Practice 2019New Biomarkers in NAFLD -- Manuel Romero-Gomez, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseEuropean Workshop on NASH in Clinical Practice 2019Patient Perspective -- Maite PujolView Slideset
VRVlad RatziuMD, PhDSlidesetViral Hepatitis and Liver DiseaseEuropean Workshop on NASH in Clinical Practice 2019Invited Lecturer -- Vlad Ratziu, MD, PhDView Slideset
JMSJörn M. SchattenbergMDSlidesetViral Hepatitis and Liver DiseaseEuropean Workshop on NASH in Clinical Practice 2019Cardiovascular Risk in NAFLD -- Jörn Schattenberg, MDView Slideset
